Pengcheng Shi

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 7

Top Topics

Acute Lymphoblastic Leukemia

Genome Wide Association Study

Top Venues

Cancer biology & therapy

Stem cell reviews and reports

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Xi Jia, Naying Liao, Sijian Yu, Huan Li, Hui Liu, Haiyan Zhang, Jun Xu, Yunqian Yao, Han He, Guopan Yu, Qi-Fa Liu, Yu Zhang, Pengcheng Shi
Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission. Cancer medicine 13 (4) (2024)
Xi Jia, Naying Liao, Yunqian Yao, Xutao Guo, Kai Chen, Pengcheng Shi
Dynamic evolution of bone marrow adipocyte in B cell acute lymphoblastic leukemia: insights from diagnosis to post-chemotherapy. Cancer biology & therapy 25 (1) (2024)
Xi Jia, Naying Liao, Yunqian Yao, Xutao Guo, Kai Chen, Pengcheng Shi
Dynamic evolution of bone marrow adipocyte in B cell acute lymphoblastic leukemia: insights from diagnosis to post-chemotherapy. Cancer biology & therapy 25 (1) (2024)
Xi Jia, Naying Liao, Yunqian Yao, Xutao Guo, Kai Chen, Pengcheng Shi
Dynamic evolution of bone marrow adipocyte in B cell acute lymphoblastic leukemia: insights from diagnosis to post-chemotherapy. Cancer biology & therapy 25 (1) (2024)
Xi Jia, Naying Liao, Yunqian Yao, Xutao Guo, Kai Chen, Pengcheng Shi
Dynamic evolution of bone marrow adipocyte in B cell acute lymphoblastic leukemia: insights from diagnosis to post-chemotherapy. Cancer biology & therapy 25 (1) (2024)
Jie Zha, Qian Lai, Manman Deng, Pengcheng Shi, Haijun Zhao, Qinwei Chen, Hua Wu, Bing Xu
Disruption of CTCF Boundary at HOXA Locus Promote BET Inhibitors' Therapeutic Sensitivity in Acute Myeloid Leukemia. Stem cell reviews and reports 16 (6) (2020)
Pengcheng Shi, Jie Zha, Juan Feng, Zhiwu Jiang, Haijun Zhao, Manman Deng, Naying Liao, Peng Li, Yirong Jiang, Haihan Song, Bing Xu
Low-Dose Triptolide Enhanced Activity of Idarubicin Against Acute Myeloid Leukemia Stem-like Cells Via Inhibiting DNA Damage Repair Response. Stem cell reviews and reports 17 (2) (2020)